deacylcortivazol: acts through glucocorticoid receptors; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3032474 |
| MeSH ID | M0093812 |
| Synonym |
|---|
| 4906-84-7 |
| deacylcortivazol |
| bimedrazole |
| 2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 11,17,21-trihydroxy-6,16-dimethyl-2'-phenyl-, (11beta,16alpha)- |
| 3jo09qt49f , |
| unii-3jo09qt49f |
| nsc 325316 |
| 11beta,17,21-trihydroxy-6,16alpha-dimethyl-2'-phenyl-2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one |
| bimedrazol |
| deacylcortivazole |
| 2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 11,17,21-trihydroxy-6,16-dimethyl-2'-phenyl-, (11.beta.,16.alpha.)- |
| ketone, 1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecahydro-1,11-dihydroxy-2,5,10a,12a-tetramethyl-7-phenylcyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-yl hydroxymethyl |
| 2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 11.beta.,17,21-trihydroxy-6,16.alpha.-dimethyl-2'-phenyl- |
| Q27257325 |
| 1-((1r,2r,3as,3bs,10ar,10bs,11s,12as)-1,11-dihydroxy-2,5,10a,12a-tetramethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl)-2-hydroxyethan-1-one |
| deacetyl cortivazol |
| 1-[(1s,2r,13s,14s,16r,17r,18s,20s)-17,20-dihydroxy-2,11,16,18-tetramethyl-7-phenyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9,11-tetraen-17-yl]-2-hydroxyethanone |
| 1-[(1s,2r,13s,14s,17r,18s,20s)-17,20-dihydroxy-2,11,16,18-tetramethyl-7-phenyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9,11-tetraen-17-yl]-2-hydroxyethanone |
| CS-0079518 |
| HY-121131 |
| AKOS040745731 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, the dose-response curves for TAT induction in HTC cells and for GS induction in FU5-5 cells are closely correlated with the saturation curve for whole cell steroid binding to receptor sites, while the dose-response curve for TAT induction in FU5-5 cells is shifted to lower steroid concentrations." | ( Dissociation of steroid binding to receptors and steroid induction of biological activity in a glucocorticoid-responsive cell. Mercier, L; Simons, SS; Thompson, EB, 1983) | 0.27 |
| " Numerous transcription factors are known to modulate three parameters of gene induction: the total activity (Vmax) and position of the dose-response curve with glucocorticoids (EC50) and the percent partial agonist activity with antiglucocorticoids." | ( Modulation of transcription parameters in glucocorticoid receptor-mediated repression. He, Y; Kagan, BL; Simons, SS; Sun, Y; Tao, YG, 2008) | 0.35 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||